Oxidative post-translational modifications and their involvement in the pathogenesis of autoimmune diseases

Redox Biology

Volumn 2, Issue 1, 2014, Pages 715-724

  Ryan, Brent J ^a   Nissim, Ahuva ^b   Winyard, Paul G ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF EXETER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AUTOANTIBODY; AUTOANTIGEN; CELL ANTIGEN; CELL NUCLEUS ANTIGEN; CHLORINE; COLLAGEN TYPE 2; COMPLEMENT COMPONENT C1Q; EPITOPE; FREE RADICAL; INDUCIBLE NITRIC OXIDE SYNTHASE; MYELOPEROXIDASE; NON NUCLEAR ANTIGEN; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; RHEUMATOID FACTOR; UNCLASSIFIED DRUG; 4 HYDROXYNONENAL; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; IMMUNOGLOBULIN G; MALONALDEHYDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ANTIBODY BLOOD LEVEL; ANTIGENICITY; APOPTOSIS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; BIOTRANSFORMATION; CARBAMOYLATION; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CITRULLINATION; DIABETOGENESIS; ENZYME ACTIVITY; GLUCOSE OXIDATION; GLYCATION; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; LIPID PEROXIDATION; NITRATION; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; CHEMISTRY; IMMUNOLOGY; METABOLISM; PATHOLOGY; ADAPTIVE IMMUNITY; ANTIBODY PRODUCTION; ANTIBODY TITER; ANTIGEN PRESENTING CELL; GENETIC CONSERVATION; IMMUNOLOGICAL TOLERANCE; IMMUNOREACTIVITY; IMMUNOREGULATION; MOLECULAR EVOLUTION; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN METABOLISM; PROTEIN STRUCTURE; TANDEM MASS SPECTROMETRY;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNE DISEASES; CHLORINE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PROTEIN PROCESSING, POST-TRANSLATIONAL; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES;

EID: 84902343228     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2014.05.004     Document Type: Review

References (106)

1. Bashir S., et al. Oxidative DNA damage and cellular sensitivity to oxidative stress in human autoimmune diseases. Annals of the Rheumatic Diseases 1993, 52(9):659-666. http://www.ncbi.nlm.nih.gov/pubmed/8239761, 10.1136/ard.52.9.659.
2. Pattison D.J., Winyard P.G. Dietary antioxidants in inflammatory arthritis: do they have any role in etiology or therapy?. Nature Clinical Practice: Rheumatology 2008, 4(11):590-596. http://www.ncbi.nlm.nih.gov/pubmed/18825134, 10.1038/ncprheum0920.
3. Szabó-Taylor K.É., et al. Oxidative stress in rheumatoid arthritis. Studies on Arthritis and Joint Disorders 2013, 145-167. Springer, New York. M.J. Alcaraz, O. Gualillo, O. Sánchez-Pernaute (Eds.).
4. Winyard P.G., et al. Measurement and meaning of markers of reactive species of oxygen, nitrogen and sulfur in healthy human subjects and patients with inflammatory joint disease. Biochemical Society Transactions 2011, 39(5):1226-1232. http://www.ncbi.nlm.nih.gov/pubmed/21936794, 10.1042/BST0391226.
5. Burska A.N., et al. Autoantibodies to posttranslational modifications in rheumatoid arthritis. Mediators of Inflammation 2014, 2014:492873. http://www.ncbi.nlm.nih.gov/pubmed/24782594.
6. Morgan P.E., Sturgess A.D., Davies M.J. Increased levels of serum protein oxidation and correlation with disease activity in systemic lupus erythematosus. Arthritis and Rheumatism 2005, 52(7):2069-2079. http://www.ncbi.nlm.nih.gov/pubmed/15986354, 10.1002/art.21130.
7. Khan F., Siddiqui A.A., Ali R. Measurement and significance of 3-nitrotyrosine in systemic lupus erythematosus. Scandinavian Journal of immunology 2006, 64(5):507-514. http://www.ncbi.nlm.nih.gov/pubmed/17032243, 10.1111/j.1365-3083.2006.01794.x.
8. Kirkham P.A., Barnes P.J. Oxidative stress in COPD. Chest 2013, 144(1):266-273. http://www.ncbi.nlm.nih.gov/pubmed/23880677, 10.1378/chest.12-2664.
9. Binder C.J., et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nature Medicine 2003, 9(6):736-743. http://www.ncbi.nlm.nih.gov/pubmed/12740573, 10.1038/nm876.
10. Kalluri R., et al. Reactive oxygen species expose cryptic epitopes associated with autoimmune Goodpasture syndrome. Journal of Biological Chemistry 2000, 275(26):20027-20032. http://www.ncbi.nlm.nih.gov/pubmed/10748075, 10.1074/jbc.M904549199.
11. Scofield R.H., et al. Modification of lupus-associated 60-kDa Ro protein with the lipid oxidation product 4-hydroxy-2-nonenal increases antigenicity and facilitates epitope spreading. Free Radical Biology and Medicine 2005, 38(6):719-728. http://www.ncbi.nlm.nih.gov/pubmed/15721982, 10.1016/j.freeradbiomed.2004.11.001.
12. Matzinger P. Tolerance, danger, and the extended family. Annual Review of Immunology 1994, 12:991-1045. http://www.ncbi.nlm.nih.gov/pubmed/8011301, 10.1146/annurev.iy.12.040194.005015.
13. Matzinger P. The danger model: arenewed sense of self. Science (New York, N.Y.) 2002, 296(5566):301-305. http://www.ncbi.nlm.nih.gov/pubmed/11951032, 10.1126/science.1071059.
14. Lichtman A.H., et al. Adaptive immunity in atherogenesis: new insights and therapeutic approaches. Journal of Clinical investigation 2013, 123(1):27-36. http://www.ncbi.nlm.nih.gov/pubmed/23281407, 10.1172/JCI63108.
15. Stavnezer J., Guikema J.E.J., Schrader C.E. Mechanism and regulation of class switch recombination. Annual Review of Immunology 2008, 26(1):261-292. http://www.ncbi.nlm.nih.gov/pubmed/18370922, 10.1146/annurev.immunol.26.021607.090248.
16. Bajénoff M., Wurtz O., Guerder S. Repeated antigen exposure is necessary for the differentiation, but not the initial proliferation, of naive CD4+ T cells. Journal of Immunology (Baltimore, Md.: 1950) 2002, 168(4):1723-1729. http://www.ncbi.nlm.nih.gov/pubmed/11823503, 10.4049/jimmunol.168.4.1723.
17. Tongren J.E., et al. Target antigen, age, and duration of antigen exposure independently regulate immunoglobulin G subclass switching in malaria. Infection and Immunity 2006, 74(1):257-264. http://www.ncbi.nlm.nih.gov/pubmed/16368979, 10.1128/IAI.74.1.257-264.2006.
18. Aalberse R.C., van der Gaag R., van Leeuwen J. Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response. Journal of Immunology (Baltimore, Md.: 1950) 1983, 130(2):722-726. http://www.ncbi.nlm.nih.gov/pubmed/6600252.
19. Casciola-Rosen L., et al. Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity. Journal of Experimental Medicine 1999, 190(6):815-826. http://www.ncbi.nlm.nih.gov/pubmed/10499920, 10.1084/jem.190.6.815.
20. Aletaha D., et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against rheumatism collaborative initiative. Arthritis and Rheumatism 2010, 62(9):2569-2581. http://www.ncbi.nlm.nih.gov/pubmed/20872595, 10.1002/art.27584.
21. Schellekens G.A., et al. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. Journal of Clinical Investigation 1998, 101(1):273-281. http://www.ncbi.nlm.nih.gov/pubmed/9421490, 10.1172/JCI1316.
22. Brahms H., et al. The C-terminal RG dipeptide repeats of the spliceosomal Sm proteins D1 and D3 contain symmetrical dimethylarginines, which form a major B-cell epitope for anti-Sm autoantibodies. Journal of Biological Chemistry 2000, 275(22):17122-17129. http://www.ncbi.nlm.nih.gov/pubmed/10747894, 10.1074/jbc.M000300200.
23. Molberg O., et al. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nature Medicine 1998, 4(6):713-717. http://www.ncbi.nlm.nih.gov/pubmed/9623982, 10.1038/nm0698-713.
24. Anderton S.M. Post-translational modifications of self antigens: implications for autoimmunity. Current Opinion in Immunology 2004, 16(6):753-758. http://www.ncbi.nlm.nih.gov/pubmed/15511669, 10.1016/j.coi.2004.09.001.
25. Chou M.Y., et al. Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans. Journal of Clinical Investigation 2009, 119(5):1335-1349. http://www.ncbi.nlm.nih.gov/pubmed/19363291, 10.1172/JCI36800.
26. Eggleton P., et al. Detection and isolation of human serum autoantibodies that recognize oxidatively modified autoantigens. Free Radical Biology and Medicine 2013, 57:79-91. http://www.ncbi.nlm.nih.gov/pubmed/23246567, 10.1016/j.freeradbiomed.2012.11.006.
27. Ryan B.J., Eggleton P. Detection and characterization of autoantibodies against modified self-proteins in SLE sera after exposure to reactive oxygen and nitrogen species. Methods in Molecular Biology (Clifton, N.J.) 2014, 1134:163-171. http://www.ncbi.nlm.nih.gov/pubmed/24497361, 10.1007/978-1-4939-0326-9_12.
28. Harman L.S., Mottley C., Mason R.P. Free radical metabolites of l-cysteine oxidation. Journal of Biological Chemistry 1984, 259(9):5606-5611. http://www.ncbi.nlm.nih.gov/pubmed/6325443.
29. Wood Z.A., et al. Structure, mechanism and regulation of peroxiredoxins. Trends in Biochemical Sciences 2003, 28(1):32-40. http://www.ncbi.nlm.nih.gov/pubmed/12517450, 10.1016/S0968-0004(02)00003-8.
30. Stadtman E.R., Levine R.L. Protein oxidation. Annals of the New York Academy of Sciences 2000, 899(1):191-208.
31. Simat T.J., Steinhart H. Oxidation of Free tryptophan and tryptophan residues in peptides and proteins. Journal of Agricultural and Food Chemistry 1998, 46(2):490-498. http://www.ncbi.nlm.nih.gov/pubmed/10554268, 10.1021/jf970818c.
32. Heinecke J.W., et al. Tyrosyl radical generated by myeloperoxidase catalyzes the oxidative cross-linking of proteins. Journal of Clinical Investigation 1993, 91(6):2866-2872. http://www.ncbi.nlm.nih.gov/pubmed/8390491, 10.1172/JCI116531.
33. Ischiropoulos H., et al. Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Archives of Biochemistry and Biophysics 1992, 298(2):431-437. http://www.ncbi.nlm.nih.gov/pubmed/1416974, 10.1016/0003-9861(92)90431-U.
34. Alvarez B., et al. Peroxynitrite-dependent tryptophan nitration. Chemical Research in Toxicology 1996, 9(2):390-396. http://www.ncbi.nlm.nih.gov/pubmed/8839040, 10.1021/tx950133b.
35. Hazen S.L., Heinecke J.W. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. Journal of Clinical Investigation 1997, 99(9):2075-2081. http://www.ncbi.nlm.nih.gov/pubmed/9151778, 10.1172/JCI119379.
36. Pattison D.I., Davies M.J. Kinetic analysis of the role of histidine chloramines in hypochlorous acid mediated protein oxidation. Biochemistry 2005, 44(19):7378-7387. http://www.ncbi.nlm.nih.gov/pubmed/15882077, 10.1021/bi0474665.
37. Chapman A.L.P., et al. Chlorination of bacterial and neutrophil proteins during phagocytosis and killing of Staphylococcus aureus. Journal of Biological Chemistry 2002, 277(12):9757-9762. http://www.ncbi.nlm.nih.gov/pubmed/11733505, 10.1074/jbc.M106134200.
38. Uchida K., Stadtman E.R. Modification of histidine residues in proteins by reaction with 4-hydroxynonenal. Proceedings of the National Academy of Sciences of the United States of America 1992, 89(10):4544-4548. http://www.ncbi.nlm.nih.gov/pubmed/1584790, 10.1073/pnas.89.10.4544.
39. Bruenner B.A., Jones A.D., German J.B. Direct characterization of protein adducts of the lipid peroxidation product 4-hydroxy-2-nonenal using electrospray mass spectrometry. Chemical Research in Toxicology 1995, 8(4):552-559. http://www.ncbi.nlm.nih.gov/pubmed/7548735, 10.1021/tx00046a009.
40. Miyata T., et al. Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers. Biochemical and Biophysical Research Communications 1998, 244(1):45-49. http://www.ncbi.nlm.nih.gov/pubmed/9514872, 10.1006/bbrc.1998.8203.
41. Vitek M.P., et al. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America 1994, 91(11):4766-4770. http://www.ncbi.nlm.nih.gov/pubmed/8197133, 10.1073/pnas.91.11.4766.
42. Rodriguez-Garcia J., Requena J.R., Rodriguez-Segade S. Increased concentrations of serum pentosidine in rheumatoid arthritis. Clinical Chemistry 1998, 44(2):250-255. http://www.ncbi.nlm.nih.gov/pubmed/9474020.
43. Casciola-Rosen L.A., Anhalt G., Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. Journal of Experimental Medicine 1994, 179(4):1317-1330. http://www.ncbi.nlm.nih.gov/pubmed/7511686, 10.1084/jem.179.4.1317.
44. Blanco P., et al. Increase in activated CD8+ T lymphocytes expressing perforin and granzyme B correlates with disease activity in patients with systemic lupus erythematosus. Arthritis and Rheumatism 2005, 52(1):201-211. http://www.ncbi.nlm.nih.gov/pubmed/15641052, 10.1002/art.20745.
45. Herrmann M., et al. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis and Rheumatism 1998, 41(7):1241-1250. http://www.ncbi.nlm.nih.gov/pubmed/9663482, 10.1002/1529-0131(199807)41:7<1241::AID-ART15>3.0.CO;2-H.
46. Donnelly S., et al. Impaired recognition of apoptotic neutrophils by the C1q/calreticulin and CD91 pathway in systemic lupus erythematosus. Arthritis and Rheumatism 2006, 54(5):1543-1556. http://www.ncbi.nlm.nih.gov/pubmed/16645988, 10.1002/art.21783.
47. Miller Y.I., et al. Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circulation Research 2011, 108(2):235-248. http://www.ncbi.nlm.nih.gov/pubmed/21252151, 10.1161/CIRCRESAHA.110.223875.
48. Friggeri A., et al. Participation of the receptor for advanced glycation end products in efferocytosis. Journal of Immunology (Baltimore, Md.: 1950) 2011, 186(11):6191-6198. http://www.ncbi.nlm.nih.gov/pubmed/21502377, 10.4049/jimmunol.1004134.
49. Morgan P.E., Sturgess A.D., Davies M.J. Evidence for chronically elevated serum protein oxidation in systemic lupus erythematosus patients. Free Radical Research 2009, 43(2):117-127. http://www.ncbi.nlm.nih.gov/pubmed/19096973, 10.1080/10715760802623896.
50. Wang G., et al. Markers of oxidative and nitrosative stress in systemic lupus erythematosus: correlation with disease activity. Arthritis and Rheumatism 2010, 62(7):2064-2072. http://www.ncbi.nlm.nih.gov/pubmed/20201076.
51. de Leeuw K., et al. Accumulation of advanced glycation endproducts in patients with systemic lupus erythematosus. Rheumatology (Oxford, England) 2007, 46(10):1551-1556. http://www.ncbi.nlm.nih.gov/pubmed/17848401, 10.1093/rheumatology/kem215.
52. Otaki N., et al. Identification of a lipid peroxidation product as the source of oxidation-specific epitopes recognized by anti-DNA autoantibodies. Journal of Biological Chemistry 2010, 285(44):33834-33842. http://www.ncbi.nlm.nih.gov/pubmed/20736172, 10.1074/jbc.M110.165175.
53. Arbuckle M.R., et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. New England Journal of Medicine 2003, 349(16):1526-1533. http://www.ncbi.nlm.nih.gov/pubmed/14561795, 10.1056/NEJMoa021933.
54. Kurien B.T., et al. Degree of modification of Ro60 by the lipid peroxidation by-product 4-hydroxy-2-nonenal may differentially induce Sjögren syndrome or systemic lupus erythematosus in BALB/c mice. Free Radical Biology and Medicine 2011, 50(10):1222-1233. http://www.ncbi.nlm.nih.gov/pubmed/20946951, 10.1016/j.freeradbiomed.2010.10.687.
55. Kurien B.T., et al. Immunization with 60 kD Ro peptide produces different stages of preclinical autoimmunity in a Sjögren's syndrome model among multiple strains of inbred mice. Clinical and Experimental Immunology 2013, 173(1):67-75. 10.1111/cei.12094.
56. Korb L.C., Ahearn J.M. C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited. Journal of Immunology (Baltimore, Md.: 1950) 1997, 158(10):4525-4528. http://www.ncbi.nlm.nih.gov/pubmed/9144462.
57. Botto M., et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nature Genetics 1998, 19(1):56-59. http://www.ncbi.nlm.nih.gov/pubmed/9590289, 10.1038/ng0598-56.
58. Siegert C.E., et al. Predictive value of IgG autoantibodies against C1q for nephritis in systemic lupus erythematosus. Annals of the Rheumatic Diseases 1993, 52(12):851-856. http://www.ncbi.nlm.nih.gov/pubmed/8311534, 10.1136/ard.52.12.851.
59. Trendelenburg M., et al. High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association- European Renal Association 2006, 21(11):3115-3121. http://www.ncbi.nlm.nih.gov/pubmed/16877491, 10.1093/ndt/gfl436.
60. Yin Y., et al. Diagnostic value of serum anti-C1q antibodies in patients with lupus nephritis: a meta-analysis. Lupus 2012, 21(10):1088-1097. http://www.ncbi.nlm.nih.gov/pubmed/22777943, 10.1177/0961203312451202.
61. Trinder P.K., et al. Altered (oxidized) C1q induces a rheumatoid arthritis-like destructive and chronic inflammation in joint structures in arthritis-susceptible rats. Clinical Immunology and Immunopathology 1997, 82(2):149-156. http://www.ncbi.nlm.nih.gov/pubmed/9000483, 10.1006/clin.1996.4293.
62. Ryan, B.J., The Effect of Oxidative Post-translational Modifications to C1q on its Antigenicity and Function, in Relation to the Pathogenesis of Systemic Lupus Erythematosus (Ph.D. thesis), Peninsula College of Medicine and Dentistry, Plymouth, UK, 2011.
63. Ryan B., et al. Oxidative and nitrative modification of C1q affects its structure, function and antigenicity in systemic lupus erythematosus. Free Radical Biology and Medicine 2010, 49(Suppl.):S148. 10.1016/j.freeradbiomed.2010.10.415.
64. Amara A., et al. Autoantibodies to malondialdehyde-modified epitope in connective tissue diseases and vasculitides. Clinical and Experimental Immunology 1995, 101(2):233-238. http://www.ncbi.nlm.nih.gov/pubmed/7544246, 10.1111/j.1365-2249.1995.tb08344.x.
65. Svenungsson E., et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001, 104(16):1887-1893. http://www.ncbi.nlm.nih.gov/pubmed/11602489, 10.1161/hc4101.097518.
66. Frostegard J., et al. Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis and Rheumatism 2005, 52(1):192-200. http://www.ncbi.nlm.nih.gov/pubmed/15641060, 10.1002/art.20780.
67. Chen C., Stenzel-Poore M.P., Rittenberg M.B. Natural auto- and polyreactive antibodies differing from antigen-induced antibodies in the H chain CDR3. Journal of Immunology (Baltimore, Md.: 1950) 1991, 147(7):2359-2367. http://www.ncbi.nlm.nih.gov/pubmed/1918968.
68. Mannoor K., et al. Expression of natural autoantibodies in MRL-lpr mice protects from lupus nephritis and improves survival. Journal of Immunology (Baltimore, Md.: 1950) 2012, 188(8):3628-3638. http://www.ncbi.nlm.nih.gov/pubmed/22407922, 10.4049/jimmunol.1102859.
69. Schellekens G.A., et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis and Rheumatism 2000, 43(1):155-163. http://www.ncbi.nlm.nih.gov/pubmed/10643712, 10.1002/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3.
70. Wang Z., et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nature Medicine 2007, 13(10):1176-1184. http://www.ncbi.nlm.nih.gov/pubmed/17828273, 10.1038/nm1637.
71. Jaisson S., et al. Carbamylated albumin is a potent inhibitor of polymorphonuclear neutrophil respiratory burst. FEBS Letters 2007, 581(7):1509-1513. http://www.ncbi.nlm.nih.gov/pubmed/17376441, 10.1016/j.febslet.2007.03.008.
72. Garnotel R., et al. Enhanced activation of and increased production of matrix metalloproteinase-9 by human blood monocytes upon adhering to carbamylated collagen. FEBS Letters 2004, 563(1-3):13-16. http://www.ncbi.nlm.nih.gov/pubmed/15063715, 10.1016/S0014-5793(04)00233-9.
73. Scinocca M., et al. Antihomocitrullinated fibrinogen antibodies are specific to rheumatoid arthritis and frequently bind citrullinated proteins/peptides. Journal of Rheumatology 2014, 41(2):270-279. http://www.ncbi.nlm.nih.gov/pubmed/24429169, 10.3899/jrheum.130742.
74. Shi J., et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proceedings of the National Academy of Sciences of the United States of America 2011, 108(42):17372-17377. http://www.ncbi.nlm.nih.gov/pubmed/21987802, 10.1073/pnas.1114465108.
75. Ligier S., Fortin P.R., Newkirk M.M. A new antibody in rheumatoid arthritis targeting glycated IgG: IgM anti-IgG-AGE. British Journal of Rheumatology 1998, 37(12):1307-1314. http://www.ncbi.nlm.nih.gov/pubmed/9973155, 10.1093/rheumatology/37.12.1307.
76. Griffiths H.R., Lunec J. Effect of polymorph derived oxidants on IgG in relation to rheumatoid factor binding. Scandinavian Journal of Rheumatology. Supplement 1988, 75:148-156. http://www.ncbi.nlm.nih.gov/pubmed/2853449.
77. Margiloff L., et al. Metal-catalyzed oxidation of immunoglobulin G impairs Fc receptor-mediated binding to macrophages. Free Radical Biology and Medicine 1998, 25(7):780-785. http://www.ncbi.nlm.nih.gov/pubmed/9823543, 10.1016/S0891-5849(98)00130-0.
78. Griffiths H.R., Lunec J. The C1q binding activity of IgG is modified in vitro by reactive oxygen species: implications for rheumatoid arthritis. FEBS Letters 1996, 388(2-3):161-164. http://www.ncbi.nlm.nih.gov/pubmed/8690077.
79. Uesugi M., Yoshida K., Jasin H.E. Inflammatory properties of IgG modified by oxygen radicals and peroxynitrite. Journal of Immunology (Baltimore, Md.: 1950) 2000, 165(11):6532-6537. http://www.ncbi.nlm.nih.gov/pubmed/11086095, 10.4049/jimmunol.165.11.6532.
80. Al-Shobaili H.A., et al. Hydroxyl radical modification of immunoglobulin G generated cross-reactive antibodies: its potential role in systemic lupus erythematosus. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders 2011, 4:11-19. http://www.ncbi.nlm.nih.gov/pubmed/21487454.
81. Nissim A., et al. Generation of neoantigenic epitopes after posttranslational modification of type II collagen by factors present within the inflamed joint. Arthritis and Rheumatism 2005, 52(12):3829-3838. http://www.ncbi.nlm.nih.gov/pubmed/16329077, 10.1002/art.21479.
82. Strollo R., et al. Autoantibodies to posttranslationally modified type II collagen as potential biomarkers for rheumatoid arthritis. Arthritis and Rheumatism 2013, 65(7):1702-1712. http://www.ncbi.nlm.nih.gov/pubmed/23575908, 10.1002/art.37964.
83. Trigwell S.M., et al. Islet glutamic acid decarboxylase modified by reactive oxygen species is recognized by antibodies from patients with type 1 diabetes mellitus. Clinical and Experimental Immunology 2001, 126(2):242-249. http://www.ncbi.nlm.nih.gov/pubmed/11703367, 10.1046/j.1365-2249.2001.01653.x.
84. Strollo R., et al. HLA-dependent autoantibodies against post-translationally modified collagen type II in type 1 diabetes mellitus. Diabetologia 2013, 56(3):563-572. http://www.ncbi.nlm.nih.gov/pubmed/23160643, 10.1007/s00125-012-2780-1.
85. Feghali-Bostwick C.A., et al. Autoantibodies in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2008, 177(2):156-163. http://www.ncbi.nlm.nih.gov/pubmed/17975205, 10.1164/rccm.200701-014OC.
86. Kirkham P.A., et al. Oxidative stress-induced antibodies to carbonyl-modified protein correlate with severity of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2011, 184(7):796-802. http://www.ncbi.nlm.nih.gov/pubmed/21965015, 10.1164/rccm.201010-1605OC.
87. Bronte V., et al. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. Journal of Experimental Medicine 2005, 201(8):1257-1268. http://www.ncbi.nlm.nih.gov/pubmed/15824085, 10.1084/jem.20042028.
88. De Sanctis F., et al. The emerging immunological role of post-translational modifications by reactive nitrogen species in cancer microenvironment. Frontiers in Immunology 2014, 5:69. http://www.ncbi.nlm.nih.gov/pubmed/24605112.
89. Brändlein S., et al. Natural IgM antibodies and immunosurveillance mechanisms against epithelial cancer cells in humans. Cancer Research 2003, 63(22):7995-8005. http://www.ncbi.nlm.nih.gov/pubmed/14633732.
90. Brändlein S., et al. Human monoclonal IgM antibodies with apoptotic activity isolated from cancer patients. Human Antibodies 2002, 11(4):107-119. http://www.ncbi.nlm.nih.gov/pubmed/12775891.
91. Bvollmers H.P., Brändlein S. Nature's Best weapons to fight cancer. Revival of human monoclonal IgM antibodies. Human Antibodies 2002, 11(4):131-142. http://www.ncbi.nlm.nih.gov/pubmed/12775893.
92. Peters M.J., et al. Relations between autoantibodies against oxidized low-density lipoprotein, inflammation, subclinical atherosclerosis, and cardiovascular disease in rheumatoid arthritis. Journal of Rheumatology 2008, 35(8):1495-1499. http://www.ncbi.nlm.nih.gov/pubmed/18597411.
93. Skaggs B.J., Hahn B.H., Mcmahon M. Accelerated atherosclerosis in patients with SLE: mechanisms and management. Nature Reviews: Rheumatology 2012, 8(4):214-223. http://www.ncbi.nlm.nih.gov/pubmed/22331061, 10.1038/nrrheum.2012.14.
94. Mok M.Y., et al. Systemic sclerosis is an independent risk factor for increased coronary artery calcium deposition. Arthritis and Rheumatism 2011, 63(5):1387-1395. http://www.ncbi.nlm.nih.gov/pubmed/21538320, 10.1002/art.30283.
95. Dorman J.S., et al. The Pittsburgh insulin-dependent diabetes mellitus (IDDM) morbidity and mortality study. Mortality results. Diabetes 1984, 33(3):271-276. http://www.ncbi.nlm.nih.gov/pubmed/6698317, 10.2337/diab.33.3.27110.2337/diabetes.33.3.271.
96. Tsimikas S., et al. Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. Journal of Lipid Research 2007, 48(2):425-433. http://www.ncbi.nlm.nih.gov/pubmed/17093289.
97. Horkko S., et al. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. Journal of Clinical Investigation 1999, 103(1):117-128. http://www.ncbi.nlm.nih.gov/pubmed/9884341, 10.1172/JCI4533.
98. Shaw P.X., et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. Journal of Clinical Investigation 2000, 105(12):1731-1740. http://www.ncbi.nlm.nih.gov/pubmed/10862788, 10.1172/JCI8472.
99. Itabe H., et al. Oxidized phosphatidylcholines that modify proteins: analysis by monoclonal antibody against oxidized low density lipoprotein. Journal of Biological Chemistry 1996, 271(52):33208-33217. http://www.ncbi.nlm.nih.gov/pubmed/8969177, 10.1074/jbc.271.52.33208.
100. Huang Y., et al. An abundant dysfunctional apolipoprotein A1 in human atheroma. Nature Medicine 2014, 20(2):193-203. http://www.ncbi.nlm.nih.gov/pubmed/24464187, 10.1038/nm.3459.
101. Tsimikas S., et al. Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression. Journal of the American College of Cardiology 2011, 58(16):1715-1727. http://www.ncbi.nlm.nih.gov/pubmed/21982317, 10.1016/j.jacc.2011.07.017.
102. Tangye S.G. To B1 or not to B1: that really is still the question!. Blood 2013, 121(26):5109-5110. http://www.ncbi.nlm.nih.gov/pubmed/23813936, 10.1182/blood-2013-05-500074.
103. Welling G.W., et al. Prediction of sequential antigenic regions in proteins. FEBS Letters 1985, 188(2):215-218. http://www.ncbi.nlm.nih.gov/pubmed/2411595, 10.1016/0014-5793(85)80374-4.
104. Winter J., et al. Bleach activates a redox-regulated chaperone by oxidative protein unfolding. Cell 2008, 135(4):691-701. http://www.ncbi.nlm.nih.gov/pubmed/19013278, 10.1016/j.cell.2008.09.024.
105. Herold M., et al. Anti-CCP: history and its usefulness. Clinical and Developmental Immunology 2005, 12(2):131-135. http://www.ncbi.nlm.nih.gov/pubmed/16050144, 10.1080/14767050500134217.
106. Briley-Saebo K.C., et al. Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes. Circulation 2008, 117(25):3206-3215. http://www.ncbi.nlm.nih.gov/pubmed/18541740, 10.1161/CIRCULATIONAHA.107.757120.